

November 19, 2019

Generics vs. Brands: The Hatch-Waxman Act and Pharmaceutical Patent Litigation

Time: 12:00pm - 1:00pm

Location: Gittis 214, Haaga Classroom

On Tuesday, November 19th, at noon, in Gittis 214, please join the Penn Intellectual Property Group in welcoming Robert Frederickson, a partner in Goodwin's IP Litigation group. Mr. Frederickson will lead a discussion regarding Hatch-Waxman litigation: the process, the strategies and considerations, and where the industry is moving. The Hatch-Waxman Act was enacted to streamline the process for generic pharmaceutical approvals while preserving incentives for innovation, ultimately establishing the legal and economic foundation for today's generic pharmaceutical industry. Wishbone will be provided courtesy of Goodwin.

On Tuesday, November 19th, at noon, in Gittis 214, please join the Penn Intellectual Property Group in welcoming Robert Frederickson, a partner in Goodwin's IP Litigation group. Mr. Frederickson will lead a discussion regarding Hatch-Waxman litigation: the process, the strategies and considerations, and where the industry is moving. The Hatch-Waxman Act was enacted to streamline the process for generic pharmaceutical approvals while preserving incentives for innovation, ultimately establishing the legal and economic foundation for today's generic pharmaceutical industry.

Mr. Frederickson has litigated numerous patent lawsuits in federal courts nationwide, including the Eastern District of Texas, the District of Delaware, and the District of Massachusetts. He has represented clients across a variety of industries, including pharmaceuticals, financial services, and smartphone applications. Mr. Frederickson holds a J.D. from Boston College Law School and degrees in economics and computer science from the George Washington University.

Wishbone will be provided courtesy of Goodwin.

Free



Contact Info:

Harry Gunn
Hcgunn@pennlaw.upenn.edu

Related Content:

- [Event Page](#)